Drugs / Obeldesivir
Obeldesivir
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT06682234 | Dec 2025 | Filoviridae infectious disease | Gilead Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06784973 | Mar → Apr 2025 | respiratory syncytial virus infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT06585150 | Oct 2024 → May 2025 | respiratory syncytial virus infectious disease | Gilead Sciences | Terminated | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05996744 | Dec 2023 → Feb 2024 | COVID-19 | Gilead Sciences | Terminated | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT05715528 | Feb → Nov 2023 | COVID-19 | Gilead Sciences | Completed | Missed primary |
| Phase 3 | NCT05603143 | Nov 2022 → Nov 2023 | COVID-19 | Gilead Sciences | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-16 | Gilead Sciences | Results Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations gilead.com ↗
Results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of obeldesivir, previously known as GS-5245, a novel investigational oral compound being developed by Gilead for the treatment of SARS-CoV-2 infection, showed obeldesivir reaches expected therapeutic plasma concentrations for the treatment of COVID-19. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-16 | Gilead Sciences | Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations gilead.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Obeldesivir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05603143 ↗ |
| Known as | ATV-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4863829 ↗ |
| Known as | GS-5245 | “The goal of this clinical study is to check if obeldesivir (ODV; GS-5245) is safe and well-tolerated by children with respiratory syncytial virus (RSV) infection.” NCT06784973 ↗ |
| Known as | ODV | “The goal of this clinical study is to check if obeldesivir (ODV; GS-5245) is safe and well-tolerated by children with respiratory syncytial virus (RSV) infection.” NCT06784973 ↗ |
| Action | Inhibit | “targets and inhibits the SARS-CoV-2 RNA-dependent RNA polymerase Nsp12” PMID 41565160 ↗ Jan 2026 |
| Modality | Small molecule | “Obeldesivir is an oral nucleoside analog prodrug” PMID 41565160 ↗ Jan 2026 |
| Route | Oral | “Tablets administered orally without regard to food.” NCT05603143 ↗ |